A5048820442- Cancer therapeutics and mechanisms
- Cancer-related Molecular Pathways
- Metal complexes synthesis and properties
- DNA Repair Mechanisms
- Ubiquitin and proteasome pathways
- Cell death mechanisms and regulation
- Histone Deacetylase Inhibitors Research
- Lung Cancer Research Studies
- Drug Transport and Resistance Mechanisms
- Cancer Cells and Metastasis
- Cancer Research and Treatments
- Cancer Mechanisms and Therapy
- RNA Interference and Gene Delivery
- Cancer Treatment and Pharmacology
- Bioactive Compounds and Antitumor Agents
- Epigenetics and DNA Methylation
- Click Chemistry and Applications
- Glycosylation and Glycoproteins Research
- Cancer, Hypoxia, and Metabolism
- Melanoma and MAPK Pathways
- PI3K/AKT/mTOR signaling in cancer
- Ovarian cancer diagnosis and treatment
- Genomics, phytochemicals, and oxidative stress
- Sulfur Compounds in Biology
- Cell Adhesion Molecules Research
Fondazione IRCCS Istituto Nazionale dei Tumori
2016-2025
Mylan (Switzerland)
2014-2021
University of Milan
2001-2019
University of Brescia
2016
University of Turin
2016
Surgical Specialties (United States)
2016
Mylan (South Africa)
2015
United States Nuclear Regulatory Commission
2013
Mario Negri Institute for Pharmacological Research
2010
Sigma Tau (Italy)
2010
The identification of lung tumor-initiating cells and associated markers may be useful for optimization therapeutic approaches predictive prognostic information in cancer patients. CD133, a surface glycoprotein linked to organ-specific stem cells, was described as marker cancer-initiating different tumor types. Here, we report that CD133+, epithelial-specific antigen-positive (CD133+ESA+) population is increased primary nonsmall cell (NSCLC) compared with normal tissue has higher tumorigenic...
The hypothesis that FasL expression by tumor cells may impair the in vivo efficacy of antitumor immune responses, through a mechanism known as ‘Fas counterattack,’ has been recently questioned, becoming object an intense debate based on conflicting results. Here we definitely show is indeed detectable cytoplasm melanoma and its confined to multivesicular bodies contain melanosomes. In these structures colocalizes with both melanosomal (i.e., gp100) lysosomal CD63) antigens. Isolated...
Metastasis is the main reason for lung cancer-related mortality, but little known about specific determinants of successful dissemination from primary tumors and metastasis initiation. Here, we show that CD133(+)/CXCR4(+) cancer-initiating cells (CIC) directly isolated patient-derived xenografts (PDX) non-small cell cancer are endowed with superior ability to seed initiate at distant organs. We additionally report CXCR4 inhibition successfully prevents increase cisplatin-resistant in...
PURPOSE: The p53 gene plays a critical role in cellular response to DNA damage and has been implicated the platinum compounds ovarian carcinoma patients. Because taxanes could induce p53-independent apoptosis, we assessed relevance of status patients receiving paclitaxel platinum-containing chemotherapy. PATIENTS AND METHODS: Forty-eight previously untreated with advanced disease received standard paclitaxel/platinum-based In tumor specimens collected at time initial surgery, before therapy,...
Since drug resistance is a complex and multifactorial event involving activation/repression of multiple biochemical pathways, we used proteomic approach to study cisplatin response in human tumor cell lines. The cervix squamous carcinoma line A431 its cisplatin-resistant subline, A431/Pt, were as model system. experimental set-up involved not just two-way comparison the control vs. drug-resistant line, but also an acute treatment both lines, leading four-way comparison, follows: 1) A431/Pt...
PLX4032/vemurafenib is a first-in-class small-molecule BRAFV600E inhibitor with clinical activity in patients BRAF mutant melanoma. Nevertheless, drug resistance develops treated patients, and strategies to overcome primary acquired are required. To explore the molecular mechanisms involved PLX4032, we investigated its effects on cell proliferation signaling panel of 27 genetically characterized patient-derived melanoma lines. Cell sensitivity PLX4032 was dependent independent from other...
Dysfunctions of lipid metabolism are associated with tumor progression and treatment resistance cutaneous melanoma. BRAF/MEK inhibitor is linked to alterations melanoma pathways. We evaluated whether a specific pattern characterizes plasma from patients their response therapy. Plasma samples controls were analyzed for FASN DHCR24 levels lipidomic profiles. expression resulted in association disease condition related cholesterol triglycerides at different stages (n = 144) as compared 115)....
Multinuclear platinum compounds have been designed to circumvent the cellular resistance conventional platinum-based drugs. In an attempt examine basis of preclinical antitumor efficacy a novel multinuclear compound (BBR 3464) in treatment cisplatin-resistant tumors, we performed comparative study cisplatin and BBR 3464 human osteosarcoma cell line (U2-OS) vitro selected subline (U2-OS/Pt). A marked increase cytotoxic potency comparison with U2-OS cells complete lack cross-resistance...
Multinuclear platinum compounds were rationally designed to bind DNA in a different manner from that of cisplatin and its mononuclear analogues. A triplatinum compound the series (BBR 3464) was selected for preclinical development, since, spite charged nature, it very potent as cytotoxic agent effective against cisplatin-resistant tumour cells. Anti-tumour efficacy studies performed panel human xenografts refractory or poorly responsive cisplatin. The novel exhibited all tested tumours an...
In an attempt to synthesize potential anticancer agents acting by inhibition of topoisomerase I (Topo I) a new series oxyiminomethyl derivatives in position 7 camptothecin (CPT) was prepared. The synthesis relied on the condensation 20S-CPT-7-aldehyde or 20S-CPT-7-ketones with alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl O-substituted hydroxylamines. compounds were tested for their cytotoxic activity vitro against H460 non-small lung carcinoma cell line, being 24 out 37 0.01-0.3...